H

Herantis Pharma Oyj
OMXH:HRTIS

Watchlist Manager
Herantis Pharma Oyj
OMXH:HRTIS
Watchlist
Price: 1.555 EUR -5.76%
Market Cap: 31.3m EUR
Have any thoughts about
Herantis Pharma Oyj?
Write Note

Operating Margin
Herantis Pharma Oyj

0%
Current
0%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-193.6k
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FI
Herantis Pharma Oyj
OMXH:HRTIS
31.3m EUR N/A
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
754.3B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
350.5B USD
28%
US
Merck & Co Inc
NYSE:MRK
252.9B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
150.5B USD
22%
Country FI
Market Cap 31.3m EUR
Operating Margin N/A
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 754.3B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 350.5B USD
Operating Margin
28%
Country US
Market Cap 252.9B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 150.5B USD
Operating Margin
22%
No Stocks Found

Herantis Pharma Oyj
Glance View

Market Cap
31.3m EUR
Industry
Pharmaceuticals

Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

HRTIS Intrinsic Value
0.172 EUR
Overvaluation 89%
Intrinsic Value
Price
H

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-193.6k
/
Revenue
0
What is the Operating Margin of Herantis Pharma Oyj?

Based on Herantis Pharma Oyj's most recent financial statements, the company has Operating Margin of 0%.